<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547091</url>
  </required_header>
  <id_info>
    <org_study_id>Alliancells-1</org_study_id>
    <nct_id>NCT01547091</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis</brief_title>
  <acronym>RA</acronym>
  <official_title>Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliancells Bioscience Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alliancells Bioscience Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic
      inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the
      destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis
      is that umbilical cord-derived mesenchymal stem cell (UC-MSCs) has anti-inflammatory effects
      and thus potentially alleviates the progression of rheumatoid arthritis. The study is to
      explore the safety and efficacy of UC-MSCs transplantation in treatment of rheumatoid
      arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was supported by the National Natural Science Foundation of China (30872618)，The
      Shanxi Province Social Development Public Relations Project (2012K13-02-35), and The Military
      Medicine and Public Health Plan (CLZ120GA23)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MSC treatment.</measure>
    <time_frame>six months</time_frame>
    <description>Adverse Events will be recorded in a patient or clinical investigation subject who administers MSC and will be evaluated a causal relationship with the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RA Serology</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Rheumatoid Factor, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS 28) Index Mean Change From Baseline</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of pain.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>UC-MSCs Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC-MSC+DMARDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated in combination with UC-MSC and DMARDS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)</intervention_name>
    <description>-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.</description>
    <arm_group_label>UC-MSCs Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)</intervention_name>
    <description>-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.</description>
    <arm_group_label>DMARDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UC-MSC+DMARDS</intervention_name>
    <description>The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.</description>
    <arm_group_label>UC-MSC+DMARDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients fulfilled the classification criteria (2010) for rheumatoid arthritis,
             man or woman aged from 18 to 70 years old.

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent in accordance with the institutional and hospital guidelines.

          -  Women of reproductive potential may not participate unless they have agreed to use an
             effective contraceptive method while on this trial. Women of child-bearing potential
             must have a pregnancy test performed within 72 hours prior to initiation of treatment.

        Exclusion Criteria:

          -  Any history of ongoing, significant or recurring infections.

          -  Any active inflammatory diseases other than RA.

          -  Significant cardiac or pulmonary disease.

          -  End-stage renal failure.

          -  Pregnant or nursing women may not participate due to the possibility of fetal harm or
             harm to nursing infants from this treatment regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingyuan Wu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Union Stem Cell &amp; Gene Engineering Co.,Ltd，Alliancells Biosciences Co., Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongjun Liu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliancells Biosciences Co., Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liming Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>The 323 Hospital of Chinese People's Liberation Army</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haijie Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliancells Biosciences Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingyuan Wu, MD,PhD</last_name>
    <phone>86-10-63188123</phone>
    <email>mingyuan-wu@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haijie Ji, MD</last_name>
    <phone>86-10-63188853</phone>
    <email>jihaijie82@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 323 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liming Wang, MD</last_name>
      <phone>86-29-84756502</phone>
      <email>wanglm@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Liming Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang H, Wu M, Liu Y. Are mesenchymal stem cells major sources of safe signals in immune system? Cell Immunol. 2012;272(2):112-6. doi: 10.1016/j.cellimm.2011.10.010. Epub 2011 Oct 29. Review.</citation>
    <PMID>22138499</PMID>
  </reference>
  <reference>
    <citation>Wang L, Ji H, Zhou J, Xie J, Zhong Z, Li M, Bai W, Li N, Zhang Z, Wang X, Zhu D, Liu Y, Wu M. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013;2013:146347. doi: 10.1155/2013/146347. Epub 2013 Mar 3.</citation>
    <PMID>23533920</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 4, 2013</submitted>
    <returned>November 15, 2013</returned>
    <submitted>April 13, 2015</submitted>
    <returned>April 28, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

